Clinical trials: Relapsed Ovarian Cancer
Ovarian Cancer
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
- Trial name
- NCT00170573
- Testing
- Caelyx
- Volunteers
- 77 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Recurrent Ovarian Epithelial Cancer
Oxaliplatin and Topotecan in Advance Ovarian Cancer
This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
- Trial name
- NCT00313612
- Testing
- oxaliplatin, topotecan
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer
- Trial name
- NCT00083122
- Testing
- cisplatin, alvocidib, cisplatin/flavopiridol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
- Trial name
- NCT02537444
- Testing
- Acalabrutinib, acalabrutinib and pembrolizumab combination
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Acerta Pharma BV
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study LY2228820 for Recurrent Ovarian Cancer
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01663857
- Testing
- LY2228820, Carboplatin, Gemcitabine
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 118 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
Ovarian Neoplasm
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal…
- Trial name
- COHORT-A (NCT05751629)
- Testing
- Dostarlimab, Bevacizumab, Niraparib
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tesaro, Inc.
Lymphomas, Solid Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Background: Methoxyamine hydrochloride (TRC102) is a new cancer treatment drug that may help improve the results of chemotherapy.
- Conditions
- Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma
- Trial name
- NCT01851369
- Testing
- TRC102, CT scan, Lomotil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01720173
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 40 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Endometrial Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00545792
- Testing
- Avastin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
- Trial name
- NCT00113607
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 111 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00023712
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Progesterone can cause the growth of ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00459290
- Testing
- mifepristone
- Where
- 22 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00702299
- Testing
- cisplatin, paclitaxel, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Ovarian Neoplasms
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
This study will assess the efficacy and safety of pembrolizumab (MK-3475) monotherapy in female participants with recurrent ovarian cancer (ROC) who have received up to 5 prior lines of treatment including platinum-based…
- Trial name
- NCT02674061
- Testing
- Pembrolizumab
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Cancer, Ovarian Cancer
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
The purpose of this study is to evaluate the effectiveness of the combination of Avastin and Docetaxel in the treatment of women with platinum sensitive recurrent epithelial ovarian cancer within 12 months of platinum…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
- Trial name
- NCT00504257
- Testing
- Avastin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This pilot, phase II trial studies how well everolimus and letrozole work in treating patients with hormone receptor positive ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back.
- Conditions
- Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma
- Trial name
- NCT02283658
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic